风湿病患者接受高风险免疫抑制剂时PJP预防模式
基于大型医疗系统电子健康记录,纳入316例新使用免疫抑制剂且诊断为血管炎、肌炎或系统性红斑狼疮的患者,随访23.2±14.2个月。39%患者接受PJP预防,但高风险条件或药物中至少25%未预防;640患者年随访无PJP感染,抗生素不良事件发生率为2.2%/患者年。
要点
- 高风险风湿病患者中PJP预防实施不一致,至少25%未接受预防。
- 640患者年随访未发现PJP感染,包括未预防者。
- 预防性抗生素不良事件发生率为2.2%/患者年,需个性化风险评估。
核心结论
- 风湿病患者PJP预防模式不一致,高风险条件或药物中约四分之一未预防,但PJP感染率极低而抗生素不良事件可检测,需个性化风险评估证据。
研究设计与样本
- 基于大型医疗系统电子健康记录,纳入316例新使用免疫抑制剂且诊断为血管炎、肌炎或系统性红斑狼疮的患者,随访23.2±14.2个月。
主要发现
- 124例(39%)患者接受PJP预防性抗生素。
- 高风险条件(如血管炎)或高风险免疫抑制剂(如环磷酰胺)中至少25%患者未接受PJP预防。
- 640患者年随访期间未发现PJP感染,包括未预防者。
- 抗生素不良事件总体发生率为2.2%/患者年。
临床怎么用
- 临床需认识到PJP预防实施不一致,对高风险风湿病患者应个体化评估预防指征。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION/OBJECTIVES: Pneumocystis jirovecii pneumonia (PJP) is a rare but potentially fatal opportunistic infection; however, consensus varies around which conditions or medications confer a level of risk sufficient to justify antibiotic prophylaxis for PJP. We used electronic health record (EHR) data to assess the current patterns of PJP prophylaxis, PJP outcomes, and prophylaxis-related adverse events among patients with rheumatic diseases who were receiving high-risk immunosuppressant drugs. METHODS: Data derive from the EHR of a large health system. We included new immunosuppressant users with diagnoses of vasculitis, myositis, or systemic lupus erythematosus. We calculated the proportion of patients who received PJP prophylaxis for each diagnosis and drug combination. We also calculated the number of PJP infections and the number of antibiotic adverse drug events (ADEs) per patient-year of exposure. RESULTS: We followed 316 patients for 23.2 + /- 14.2 months. Overall, 124 (39%) of patients received prophylactic antibiotics for PJP. At least 25% of patients with the highest risk conditions (e.g. vasculitis) or highest risk immunosuppressants (e.g. cyclophosphamide) did not receive PJP prophylaxis. We found no cases of PJP infection over 640 patient-years of follow up, including among those not receiving prophylaxis, and an overall incidence rate of ADEs of 2.2% per patient-year. CONCLUSIONS: PJP prophylaxis for patients with rheumatic conditions is inconsistent, with one quarter of patients who have high risk conditions or high risk immunosuppressants not receiving prophylaxis. However, given extremely low rates of PJP infection, but detectable ADEs to prophylactic antibiotics, our findings suggest that evidence to guide more personalized risk assessments are needed to inform PJP prophylaxis.
引用
- Schmajuk G, Jafri K, Evans M, et al. Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs. Semin Arthritis Rheum. 2018. PMID: 30449650. doi:10.1016/j.semarthrit.2018.10.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。